Shragai T, Lavi N, Vaxman I, Gatt ME, Chubar E, Ganzel C, Magen H, Luttwak E, Mittelman M, Trestman S, Lebel E, Saban R, Vainstein V, Zuckerman T, Horowitz N, Tzoran I, Horesh N, Lowenton-Spier N, Melamed N, Pereg I, Avivi I, Cohen YC. Ixazomib, pomalidomide and dexamethasone in triple-class exposed multiple myeloma patients - a phase II study. haematol [Internet]. 2020Sep.10 [cited 2026Sep.11];. Available from: https://haematologica.org/article/view/14407